PiQo4: Complete Buyer's Guide

PiQo4 is marketed around four wavelengths: 1064 nm, 532 nm, 585 nm and 650 nm. The core platform uses 1064 nm Q-switched Nd:YAG output with 532 nm KTP conversion and pulse slicing, while 585 nm and 650 nm are provided through dye handpieces.

This combination gives PiQo4 broad advertised tattoo-color coverage. However, the four-wavelength marketing story should not be interpreted as four identical primary channels: the 585 nm and 650 nm dye accessories have different energy, spot-size and accessory limitations than the core 1064/532 nm system.

For buyers, the important distinction is between the marketed wavelength set and the specific FDA-cleared indications and configuration actually included with the unit being purchased.

PiQo4 combines conventional Q-switched nanosecond operation with a pulse-slicing architecture that produces approximately 500 picosecond pulses at 1064 nm and 532 nm.

The shorter pulse is created by diverting portions of the Q-switched pulse through an electro-optic pulse-slicing module. This is technically different from a native short-cavity picosecond architecture.

The dual nano-plus-pico architecture gives operators flexibility for different pigment particle sizes and treatment strategies. Buyers should obtain the serial-specific technical schedule rather than assuming that every energy level is available at every pulse duration.

Fractional delivery can extend the platform beyond tattoo treatment into skin-focused applications. However, buyers should verify exactly which fractional handpiece or accessory is included with the quoted system and what indications are supported for that configuration.

Because PiQo4 has a legacy-product status concern in the current U.S. market, accessory availability and future support should be confirmed in writing before assigning significant business value to fractional capabilities.

PiQo4 is primarily associated with tattoo and pigment treatment. Its marketed four-wavelength architecture is designed to provide broad advertised coverage across tattoo colors, while its nano-plus-pico architecture provides flexibility for different pigment particle sizes and treatment strategies.

The foundational FDA record is narrower than some later commercial marketing. The original 510(k) clearance documents 1064 nm and 532 nm tattoo-removal indications, including 1064 nm treatment of darker inks in Fitzpatrick skin types I–VI and 532 nm treatment of red, yellow and orange inks in skin types I–III.

Therefore, buyers should distinguish between advertised platform capabilities and the exact U.S. labeling associated with the specific configuration they are purchasing.

The foundational U.S. FDA 510(k) clearance for NaturaLase PiQo4 was issued on September 1, 2015. That record identifies a 1064 nm Q-switched Nd:YAG laser, 532 nm KTP optics and pulse slicing, with tattoo-removal indications at 1064 nm and 532 nm.

• 1064 nm tattoo treatment for darker inks, including use across Fitzpatrick skin types I–VI as documented in the foundational record.
• 532 nm tattoo treatment for red, yellow and orange inks in the cleared skin-type range documented in the foundational record.
• Additional commercial claims and accessory-based applications should be checked against the actual U.S. labeling for the quoted unit.

Buyer caution: do not rely solely on later marketing material when evaluating FDA-cleared indications. Obtain the applicable labeling and clearance documentation for the exact configuration.

• High pico and nano energy: commercial specifications report up to 650 mJ at 1064 nm and 325 mJ at 532 nm in pico mode, with higher nano-mode output.
• Large spot-size availability: commercial materials describe up to 15 selectable spot sizes from 2–15 mm.
• Dual pulse-duration architecture: nano and approximately 500 ps operation provide flexibility for different pigment particle sizes and treatment approaches.
• Four marketed wavelengths: 1064, 532, 585 and 650 nm provide broad advertised tattoo-color coverage.
• Strong core tattoo labeling: the foundational FDA record documents 1064 nm and 532 nm tattoo-removal indications.
• Standard North American voltage: the executive summary identifies standard 110/120 V input as a potential ownership advantage for appropriate configurations.

The biggest PiQo4 buyer issue is not raw output; it is lifecycle and support clarity. The platform is absent from Lumenis' current U.S. aesthetics product menu, so a buyer should treat a new purchase as potentially legacy unless the seller can provide current new-sale documentation.

There is also a split manufacturer/brand history. Focus Medical is identified as the FDA applicant/legal manufacturer in the foundational record, while Lumenis commercially marketed the platform. The party responsible for parts, calibration, repairs and long-term service should therefore be confirmed for the exact serial number.

The 585 nm and 650 nm dye handpieces also deserve particular scrutiny. These accessories may have smaller fixed spots, lower energy, greater optics/consumable sensitivity and less versatility than the primary 1064/532 nm channels.

Finally, do not compare PiQo4 purely by its headline energy number. The pulse-slicing architecture creates short pulses by diverting portions of the Q-switched pulse, so the output architecture differs from native short-cavity picosecond platforms.

A standardized public warranty should not be assumed for PiQo4. The executive summary recommends obtaining the responsible service entity, warranty duration and exact parts, labor, travel and handpiece exclusions in writing.

For pre-owned units, request complete calibration and service records, shot count where available, repair history, handpiece serial numbers and confirmation that replacement parts remain obtainable.

Because PiQo4 is not visible in Lumenis' current U.S. product menu, support for the exact serial number should be treated as a purchase-critical diligence item rather than a routine assumption.